Your browser is no longer supported. Please, upgrade your browser.
MBRX Moleculin Biotech, Inc. daily Stock Chart
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own1.70% Shs Outstand59.48M Perf Week1.25%
Market Cap45.51M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float54.73M Perf Month-15.54%
Income-19.30M PEG- EPS next Q-0.09 Inst Own18.60% Short Float6.20% Perf Quarter-18.54%
Sales- P/S- EPS this Y29.30% Inst Trans-8.07% Short Ratio1.08 Perf Half Y26.56%
Book/sh0.26 P/B3.12 EPS next Y2.60% ROA-68.50% Target Price- Perf Year-26.53%
Cash/sh0.30 P/C2.72 EPS next 5Y- ROE-117.70% 52W Range0.32 - 1.97 Perf YTD-11.49%
Dividend- P/FCF- EPS past 5Y-20.70% ROI- 52W High-59.26% Beta2.17
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low148.45% ATR0.06
Employees11 Current Ratio5.30 Sales Q/Q- Oper. Margin- RSI (14)40.35 Volatility6.90% 6.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-490.30% Profit Margin- Rel Volume0.09 Prev Close0.81
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.14M Price0.80
Recom1.70 SMA20-2.60% SMA50-17.38% SMA200-13.70% Volume54,503 Change-0.93%
Sep-14-20 07:30AM  
Sep-10-20 07:30AM  
Sep-09-20 01:52PM  
Aug-27-20 07:30AM  
Aug-12-20 07:30AM  
Aug-11-20 09:13AM  
Jul-21-20 09:59AM  
Jul-16-20 11:11AM  
Jul-15-20 07:30AM  
Jul-03-20 11:30AM  
Jul-02-20 07:30AM  
Jul-01-20 05:50PM  
Jun-30-20 09:00AM  
Jun-29-20 08:35AM  
Jun-25-20 07:30AM  
Jun-23-20 08:49AM  
Jun-17-20 11:30AM  
Jun-16-20 07:30AM  
Jun-04-20 07:30AM  
Jun-02-20 07:30AM  
Jun-01-20 11:30AM  
May-27-20 05:55PM  
May-18-20 02:47PM  
May-13-20 11:30AM  
May-11-20 08:36AM  
May-08-20 05:09PM  
May-06-20 08:39AM  
May-05-20 05:45PM  
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. Zoo for the development of WP1220; collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066; and material transfer agreement with the University of Texas Medical Branch at Galveston, d/b/a UTMB Health. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.